Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03031665 · ClinicalTrials.gov registry record
Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression
A clinical trial, sponsored by Mclean Hospital.
- Completed
- Registry status
- 251
- Enrollment target
NCT03031665: Completed study, sponsored by Mclean Hospital.
NCT03031665 is a clinical trial that has completed, run by Mclean Hospital. The registered enrollment target is 251 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03031665 has completed, sponsored by Mclean Hospital.
- COMPLETED
- Registry status
- 251 participants
- Enrollment target
Study Summary
Using an innovative multi-modal imaging approach, this study investigates the role of the neurochemical gamma-aminobutyric acid (GABA), brain activity, as well as hormones in understanding sex differences in Major Depressive Disorder (MDD). Further, the investigators will link these markers to symptoms of depression.
Primary Outcome
Region-specific BOLD activation in response to stress in hypothalamus, amygdala, medial prefrontal cortex, orbitofrontal cortex, anterior cingulate cortex, and hippocampus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 251 participants |
| Start Date | 2017-10-01 |
| Est. Completion | 2022-06-15 |
What the finished NCT03031665 record still lists
NCT03031665 is an observational study that tracks outcomes without assigning an intervention. The registered 251 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT03031665 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03031665 about?
NCT03031665 is a clinical study titled "Sex, Hormones and Gamma-Aminobutyric Acid (GABA) in Stress Induced Anhedonia in Depression". Using an innovative multi-modal imaging approach, this study investigates the role of the neurochemical gamma-aminobutyric acid (GABA), brain activity, as well as hormones in understanding sex differences in Major Depressive Disorder (MDD). Further, the investigators will link these markers to sympt...
What is the current status of trial NCT03031665?
This trial is currently completed. The enrollment target is 251 participants. The study started on 2017-10-01. Estimated completion is 2022-06-15.
Who is sponsoring clinical trial NCT03031665?
This trial is sponsored by Mclean Hospital, which has 140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06043817 · 251 participants · Phase 1
First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations
- NCT02314988 · 252 participants · Phase 2
Tranexamic Acid to Reduce Blood Loss in Spine Surgery
- NCT03941756 · 252 participants · NA
Lymphovenous Bypass Procedure Before Underarm Lymph Node Surgery in Preventing Lymphedema in Patients With Inflammatory or Locally Advanced Non-inflammatory Breast Cancer or Melanoma
- NCT05219617 · 252 participants · Phase 3
Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI